Oral suspension, 60 ml after reconstitution, where each 5 ml contains 125 mg cefdinir.
Contains the active ingredient cefdinir, an extended-spectrum, semisynthetic third generation cephalosporin, for oral administration.
Bactericidal activity of cefdinir results from inhibition of cell wall synthesis .Cefdinir has been shown to be active against most strains of the following microorganisms .Aerobic gram –positive microorganisms as staphylococcus aureus (including B lactamase producing strain ) ,streptococcus pneumoniae ,streptococcus pyogenes.Aerobic gram – negative microorganisms as haemophilus influenzae ,haemophilus parainfluenzae ,moraxella catarrhalis (including B lactamase producing strain ) .
1-Acute bacterial otitis media.
2-Pharyngitis/ Tonsillitis caused by Streptococcus pyogenes .
3-Uncomplicated skin and skin structural infections caused by
Staphylococcus aureas and streptococcus pyogenes .
Children:7 mg /kg /dose twice daily for 5-10 days or 14 mg /kg/dose once daily for 10 days (maximum 600 mg/day).
-Dosing adjustment in renal impairment: CLcr<30 ml/minute: 300 mg once daily.
Haemodialysis removes cefdinir: recommended initial dose: 300 mg or 7 mg/kg/dose every other day. At the conclusion of each haemodialysis session, 300 mg or 7 mg/kg should be given.
In patients with known allergy to the cephalosporin class of antibiotics.
Box contains 1 bottle of 60 ml.